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At present, lung cancer remains the first cause of cancer-
related death worldwide, and non-small cell lung cancer 
(NSCLC) accounts for 80% of cases. Despite advances in 
the treatment of NSCLC, patient prognosis remains dismal, 
with overall survival rates ranging from 55% in local disease 
to 4% in metastatic disease. This scenario, combined 
with the absence of proper screening tools, highlights the 
urgency of developing new diagnostic biomarkers that can 
identify lung cancer patients at early-stage where surgery 
with curative intent is the preferred treatment. Although 
early diagnosis is related to increased survival, in the first 
five years after surgery, up to 40% of resected patients 
relapse (1). Therefore, it also urges the development of new 
biomarkers to identify lung cancer patients with a high risk 
of relapse after surgery in order to improve their clinical 
management and survival.
In this line, the study of long non-coding RNAs 
(lncRNAs) has emerged as one of the most promising 
fields in the development of new biomarkers for all cancer 
types, including NSCLC (2-4). LncRNAs display an 
extremely specific expression pattern, and their capacity to 
discriminate between tumor and normal tissue is superior to 
coding genes or pseudogenes, making them an ideal source 
of biomarkers (5). 
The recently published manuscript by Acha-Sagredo et al. 
reports their study of deregulated lncRNAs associated with 
NSCLC pathogenesis (6) and provides some additional 
information to the state of the art (2-4). This was two-
phase study (Figure 1). An initial discovery data set based 
on microarray analysis of 44 paired normal and NSCLC 
tissue was used for the identification of dysregulated 
lncRNAs in NSCLC. This discovery phase was followed 
by qPCR validation in 38 additional specimens, which was 
cross-validated using available TCGA data [n=850: lung 
adenocarcinoma (LUAD) =585; squamous cell carcinoma 
(LUSC) =504]. During the discovery phase, a total of 1122 
downregulated and 771 upregulated lncRNAs [including 
long intergenic non-coding RNAs (lincRNAs) and anti-
sense transcripts] were identified. The validation phase 
confirmed the upregulation of six lncRNAs and the 
downregulation of six other lncRNAs in tumor tissue 
compared to normal tissue. 
Some of the upregulated lncRNAs identified have 
previously been described as oncogenes in NSCLC. For 
example, LINC00673 and PCAT6 have been linked to 
several key processes in cancer progression: LINC00673 to 
epithelial-to-mesenchymal transition (EMT) and cellular 
senescence (7,8); and PCAT6 to the recruiting of chromatin-
modifying complexes (9). Consistent with these results, 
some of the downregulated lncRNAs identified in the study 
by Acha-Sagredo et al. (6) have previously been described by 
Salavaty et al. using TCGA LUAD data (10). For instance, 
they explored and confirmed the role of the lncRNAs 
LANCL1-AS1, FENDRR, LINC00968 and ADAMTS9-AS2 
as tumor suppressors in NSCLC adenocarcinoma. Salavaty 
et al. analyzed the TCGA data using two different web-
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servers, circlncRNAnet (http://app.cgu.edu.tw/circlnc/) 
and GEPIA (http://gepia.cancer-pku.cn/), and studied the 
lncRNAs that were differentially expressed on both servers. 
Interestingly, they also used data from plasma RNA-Seq 
to study circulating lncRNAs and identified SNHG6 as a 
candidate for further evaluation as a circulating biomarker 
of lung adenocarcinoma.  
While Acha-Sagredo et al. found that PCAT19 was 
downregulated in tumor tissue, Zhang et al. (11) reported 
that it was upregulated in NSCLC tumor tissue samples 
and negatively correlated with the mRNA expression of 
the TP53 gene in both normal and tumor tissue. They also 
found a correlation between high expression of PCAT19 
in tumor tissue and shorter overall survival (11), but this 
impact on survival was not observed by Acha-Sagredo 
et al. Similarly, Acha-Sagredo et al. found that LINC00968 
was downregulated in tumor tissue, but it has previously 
been reported as upregulated in tumor tissue, where it 
acted as an oncogene (12,13). The authors suggested that 
the contradictory results observed in these two lncRNAs, 
Figure 1 Experimental workflow followed in Acha-Sagredo et al. The lncRNA expression was profiled in the discovery cohort (n=44) using 
Gencode v15 microarrays, identifying 1893 differentially expressed lncRNAs between TT and paired NT. Fourteen lncRNAs were selected 
for further validation by RTqPCR. Technical (n=29) and biological (n=38) validation was achieved in 12 lncRNAs (FEZF1-AS1, LINC01214, 
LINC00673, PCAT6, NUTM2A-AS1, LINC01929, PCAT19, FENDRR, SVIL-AS1, LANCL1-AS1, ADAMTS9-AS2, LINC00968). In silico 
cross-validation was performed using TCGA data (LUAD and LUSC datasets). The concordant 12 lncRNAs between RTqPCR validation 
and in silico validation were selected for further studies including clinical-pathological correlations, study of their levels in 13 NSCLC cell 
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PCAT19 and LINC00968, could be explained by differences 
between databases annotations producing that different 
transcripts are annotated under the same name. 
Acha-Sagredo et al. further explored the differential 
expression of the dysregulated lncRNAs in normal and 
tumor tissue by comparing their expression in a panel of 13 
NSCLC cell lines and a normal lung embryonic fibroblast 
cell line (IMR-90). In our opinion, the normal cell line 
used for this comparison was not the most adequate since 
fibroblasts have a different embryonic origin (mesoderm) 
than the epithelial cells (endoderm) that trigger NSCLC. 
Probably, the selection of a normal lung epithelial cell line, 
such as BEAS-2B or other, would have been a better control 
for this comparison. Furthermore, functional studies in 
these cell lines to unravel the role in the carcinogenesis 
process of the lncRNAs identified is missing. 
The authors also analyzed the correlation between the 
expression of the lncRNAs and patient clinicopathological 
characteristics in both their cohort and in the TCGA 
dataset (Figure 2). In their cohort they found correlations 
between sex and the lncRNAs FEZF1-AS1 and ADAMTS9-
AS2 and between tumor differentiation grade and the 
lncRNAs PCAT6 and LANCL1-AS1. However, probably, 
one of the most salient findings in this line is the correlation 
between the presence of lymph node metastasis and the 
lncRNAs LINC01929 and LINC00968. Lymph node status 
(N) is a significant component of staging of NSCLC and 
is directly related to relapse rate after surgery and with 
treatment decisions. Patients are classified depending 
on the location of the metastatic lymph node as N0 (no 
nodal involvement), N1 (peribronchial, interlobar, hilar 
node involvement), N2 (ipsilateral nodal involvement) 
or N3 (contralateral mediastinal, contralateral hilar or 
supraclavicular nodal involvement (14). Although the 
authors not deepened in the study of lncRNAs and the N 
type, the identification of lncRNAs linked to N status is for 
sure of clinical importance. For instance, N2 occult lymph 
node involvement is present in 10% of stage I NSCLC 
patients and in 21% of those with stage II (15), which can 
impact the clinical management of patients. Although 
stage I patients are not usually treated with adjuvant 
chemotherapy, if N2 involvement is confirmed, they 
may increase to stage IIIA, where adjuvant treatment has 
demonstrated benefit in outcome (1,14). To our knowledge, 
the identified association between N and the lncRNAs 
LINC01929 and LINC00968 have not been previously 
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described in NSCLC, but the authors were not able to 
crossvalidate this finding in the TCGA cohort. In fact, in 
the TCGA analysis other lncRNAs from the validation list 
were significantly correlated with N, including LINC00673, 
LANCL1-AS1 and ADAMTS9-AS2, and LINC00968 was 
found with and opposite relationship than in their cohort. 
Two of the lncRNAs associated with N in the TCGA 
dataset have been previously described in the literature. 
LINC00673, which was upregulated in patients with 
lymph node involvement, has been also related to lymph 
node metastasis in gastric, thyroid, breast and ovarian 
cancer (16-19). Furthermore, ADAMTS9-AS2, which was 
downregulated in patients with lymph node involvement, 
has also been reported to be downregulated in ovarian and 
gastric cancer (20,21). Despite the differences between the 
discovery and validation cohort in this matter, the role of 
these lncRNAs in lymph node involvement merits further 
exploration and with further research and validation, they 
might become a powerful tool for clinical practice.
Finally, the authors point out that some of the studied 
lncRNA could become deregulated by alterations in the 
methylation patterns of the CpG islands located in their 
promoters. Specifically, the methylation status of 7 out 
of the 14 lncRNAs was analyzed: PCAT6, RNF139-AS1, 
LINC00673 and NUTM2A-AS1. Although the results were 
not conclusive since no correlation between expression 
levels and degree of methylation was observed in the 
paired samples, the epigenetic mechanism of lncRNA 
dysregulation is a point that deserves further study.
Research on lncRNAs needs to deal with several concerns 
to reinforce their clinical applicability. The authors denoted 
that one of the most challenging concerns in lncRNA 
research is the lack of proper annotation for most of 
these genes and the differences in sequence and genomic 
location between different databases. It is urgent, therefore, 
to increase efforts towards a global consensus on these 
issues in order to improve the replicability of the results 
and their potential clinical application (22). Moreover, 
recently, the study of biomarkers that can be screened in 
body fluids (liquid biopsy) has emerged as a key direction 
for translational research. Several studies have explored 
the role of circulating lncRNAs as diagnostic biomarkers 
in NSCLC (23). Additionally, others, including our group, 
have highlighted the synergistic advantages of exploring the 
role of lncRNAs in extracellular vesicles as part of the liquid 
biopsy (24). Furthermore, new, clinically relevant sources 
of lncRNAs have emerged, such as the use of the tumor-
draining pulmonary vein, which can be accessed during 
surgery and has proven to be enriched in primary tumor-
secreted lncRNAs (25).
In conclusion, the present study reinforces the idea that 
lncRNAs are new promising biomarkers that might help us 
to shed light on the pathological mechanisms of NSCLC 
tumorigenesis and progression, considering in our humble 
opinion, the new hidden code of NSCLC. 
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